About Innodia

Innodia

How academic researchers, industry and patients collaborate in order to fight Type 1 Diabetes.

INNODIA started as a global partnership between 31 academic institutions, 6 industrial partners, a small sized enterprise and 2 patient organizations, bringing their knowledge and experience together with one common goal: "To fight type 1 diabetes".  

The project ran under the framework of the Innovative Medicines Initiative – Joint Undertaking (IMI-JU) with a dedicated governance structure ensuring close interaction, communication and adherence to the objectives and deliverables of the consortium. Importantly, INNODIA has closely been guided by the patients themselves, through the Patient Advisory Committee, consisting of a group of type 1 diabetes patients and parents, giving continuous feedback on the concept of INNODIA and development of protocols. PAC had a crucial role crucial in disseminating the goals of INNODIA to the public.  

INNODIA examined samples and data from newly diagnosed patients with type 1 diabetes and unaffected first degree relatives throughout Europe.

Recruitment for both newly diagnosed people with T1D and relatives has ended

INNODIA is very thankful for all people with T1D and their close family members who contributed to the progress in the project. Collected samples and data are being examined in great detail.

From the start, another major goal of INNODIA, was to undertake clinical intervention studies. With those trials, we want to halt the further decline in beta cell functionality in people with newly diagnosed T1D, addressing the immune system or the beta cells by different treatment modalities. In 2020 INNODIA started 4 clinical trials.
Only one study is still ongoing and in the final stage of recruitment. We're nearly there! Here again, pharmaceutical companies being part of INNODIA join forces with leading academic clinical researchers to prove the effectiveness of these potential new therapeutic agents.